• Daniel B Eidman, Christie L Clauss, Sarah A Kelly, Joanna M Rhieu, Sarah McCollum, and G CoulouresKevinKDepartment of Pediatrics, Section of Critical Care Medicine, Yale University School of Medicine, New Haven, Connecticut; and Department of Pediatrics, Division of Critical Care Medicine, Stanford School of Medicine, Stanford, California..
• Department of Pediatrics, Section of Critical Care Medicine, Yale University School of Medicine, New Haven, Connecticut; and Department of Pediatrics, Division of Pediatric Critical Care, NYU Langone Health, New York, New York. daniel.eidman@nyulangone.org.
• Respir Care. 2022 Mar 1; 67 (3): 301307301-307.

BackgroundNoninvasive ventilation (NIV) facilitates management of acute respiratory failure without intubation. Many pediatric patients cannot tolerate the discomfort associated with noninvasive support and require sedation with agents that may decrease respiratory drive. Dexmedetomidine does not decrease respiratory drive, and we hypothesized that its use would increase tolerance of noninvasive respiratory support without increasing risk for intubation.MethodsA retrospective chart review was performed of all subjects at least 3 months of age with acute respiratory failure requiring NIV who were admitted to the pediatric ICU at a children's hospital for a 3-y period from 2015-2018. Subjects were stratified to those receiving continuous dexmedetomidine versus those not receiving sedation. Medical history was reviewed for developmental delay (DD) or intellectual disability (ID) as well as basic demographic information. To control the association between these variables with both dexmedetomidine use and intubation, augmented inverse probability weighting was utilized to establish equivalent baselines between the dexmedetomidine and no-sedation groups. Primary outcome was intubation rate within 6 h of initiation of dexmedetomidine infusion or NIV.ResultsBased on the strong association between age and dexmedetomidine use, a statistical model including subjects > age 5 was not able to be generated, and these subjects were excluded from final analysis. One-hundred eight subjects were included in the final statistical analysis, with 60 receiving dexmedetomidine and 48 receiving no sedation. Dexmedetomidine was effective at reducing agitation, with no difference noted in intubation rate at 6 h between subjects receiving dexmedetomidine versus no sedation (13.1 vs 12.4%).ConclusionsDexmedetomidine may allow tolerance of NIV in acute respiratory failure without increasing risk for intubation, especially in preschool age patients and those with DD or ID. A larger study involving multiple centers would help support our conclusions.Copyright © 2022 by Daedalus Enterprises.

13 keywords...

hide…